Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305126 | 0.90 | DGAT1 (0.37) | DGAT1ROCK2PIM1PIM3 | |
| SCHEMBL3298307 | 0.88 | HSD11B1 (0.32) | DGAT1HSD11B1HTR6 | |
| SCHEMBL3305263 | 0.86 | MAPT (0.32) | DGAT1 | |
| SCHEMBL3298942 | 0.86 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3366649 | 0.86 | ITGA4 (0.35) | ROCK2PIM1PIM3HSD11B1PLA2G4A | |
| SCHEMBL3302802 | 0.85 | ACLY (0.40) | DGAT1HTR6 | |
| SCHEMBL3297421 | 0.85 | LMNA (0.33) | DGAT1HSD11B1HTR6 | |
| SCHEMBL3298668 | 0.85 | NR3C1 (0.34) | DGAT1NR3C1 | |
| SCHEMBL3299721 | 0.85 | DGAT1 (0.33) | DGAT1ROCK2PIM1PIM3 | |
| SCHEMBL3298987 | 0.84 | ROCK2 (0.50) | ROCK2PIM1PIM3HSD11B1PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | DGAT1 3856/4885ROCK2 1978/4885PIM1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.